Trials / Completed
CompletedNCT02189837
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Evolocumab | Administered by subcutaneous injection |
| DRUG | Atorvastatin | Administered by mouth |
| DRUG | Placebo to Evolocumab | Administered by subcutaneous injection |
| DRUG | Placebo to Atorvastatin | Administered by mouth |
Timeline
- Start date
- 2014-07-08
- Primary completion
- 2015-02-13
- Completion
- 2015-03-05
- First posted
- 2014-07-15
- Last updated
- 2018-10-03
- Results posted
- 2016-08-31
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02189837. Inclusion in this directory is not an endorsement.